The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Syndecans (13–16) and perlecan (14, 17, 18) have been shown to mediate the internalization of model remnant lipoproteins or TRL preparations enriched in LPL or apoE.”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, we believe that the genetic data presented here and previously (9), coupled with numerous cell culture studies by other groups over the years (13–19, 21), argue for independent action of proteoglycans in the hepatic”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“coupled with numerous cell culture studies by other groups over the years (13–19, 21), argue for independent action of proteoglycans in the hepatic clearance of triglyceride-rich remnants.”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interestingly, livers from insulin-deficient rodents show reduced HS production (66, 67), reduced sulfation of the chains (68), and decreased expression of Ndst1 (69,70).”
From Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members (2007) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rohlmann, A., Gotthardt, M., Hammer, R. E., & Herz, J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1240 · Cited by 455 · cited 2×
“In otherwise normal mice, decreased LRP activity produces LDL-R upregulation and increased plasma apoB48 but no significant alterations in plasma TG and cholesterol have been reported (72).”
Background
Research works printed but not linked: 90
- Królewski, 1987, Am J Cardiol, 59, 750, 10.1016/0002-9149(87)91086-1 · DOI
- Jensen, 1987, Diabetologia, 30, 144, 10.1007/BF00274218 · DOI
- Winocour, 1989, Q J Med, 70, 265
- 1992, Diabetes Care, 15, 886, 10.2337/diacare.15.7.886 · DOI
- Rivellese, 1988, Diabetologia, 31, 884, 10.1007/BF00265371 · DOI
- Patti, 1993, Diabetologia, 36, 155, 10.1007/BF00400698 · DOI
- Perez, 1997, Diabetes Res Clin Pract, 36, 83, 10.1016/S0168-8227(97)00033-8 · DOI
- Dunn, 1992, Diabetes, 41(Suppl. 2), 102, 10.2337/diab.41.2.S102 · DOI
- Georgopoulos, 1991, J Lipid Res, 32, 1133, 10.1016/S0022-2275(20)41976-5 · DOI
- Phillips, 1993, Circulation, 88, 2762, 10.1161/01.CIR.88.6.2762 · DOI
- Groot, 1991, Arterioscler Thromb, 11, 653, 10.1161/01.ATV.11.3.653 · DOI
- Ginsberg, 1995, Arterioscler Thromb Vasc Biol, 15, 1829, 10.1161/01.ATV.15.11.1829 · DOI
- Sharrett, 1995, Arterioscler Thromb Vasc Biol, 15, 2122, 10.1161/01.ATV.15.12.2122 · DOI
- Cooper, 1997, J Lipid Res, 38, 2173, 10.1016/S0022-2275(20)34932-4 · DOI · Paper page
- Fried, 1993, J Clin Invest, 92, 2191, 10.1172/JCI116821 · DOI
- Ginsberg, 1991, Diabetes Care, 14, 839, 10.2337/diacare.14.9.839 · DOI
- Eckel, 1988, Diabetes, 37, 610, 10.2337/diab.37.5.610 · DOI
- Tsutsumi, 1995, Diabetes, 44, 414, 10.2337/diab.44.4.414 · DOI
- Shimada, 1995, Arterioscler Thromb Vasc Biol, 15, 1688, 10.1161/01.ATV.15.10.1688 · DOI
- Li, 1995, J Clin Invest, 96, 2601, 10.1172/JCI118324 · DOI · Paper page
- Brown, 1972, Biochem Biophys Res Commun, 46, 375, 10.1016/S0006-291X(72)80149-9 · DOI
- Havel, 1973, Biochemistry, 12, 1828, 10.1021/bi00733a026 · DOI
- Ebara, 1997, J Clin Invest, 99, 2672, 10.1172/JCI119456 · DOI
- Kowal, 1990, J Biol Chem, 265, 10771, 10.1016/S0021-9258(18)87014-4 · DOI · Paper page
- Windler, 1980, J Biol Chem, 255, 10464, 10.1016/S0021-9258(19)70487-6 · DOI
- Sehayek, 1991, J Biol Chem, 266, 18259, 10.1016/S0021-9258(18)55263-7 · DOI · Paper page
- Al Muhtaseb, 1992, Pediatrics, 89, 936, 10.1542/peds.89.5.936 · DOI
- Al-Muhtaseb, 1991, Diabet Med, 8, 732, 10.1111/j.1464-5491.1991.tb01692.x · DOI
- Rubinsztein, 1990, J Clin Invest, 86, 1306, 10.1172/JCI114839 · DOI · Paper page
- Hui, 1981, J Biol Chem, 256, 5646, 10.1016/S0021-9258(19)69254-9 · DOI · Paper page
- Kita, 1982, Proc Natl Acad Sci USA, 9, 3623, 10.1073/pnas.79.11.3623 · DOI · Paper page
- Herz, 1988, EMBO J, 7, 4119, 10.1002/j.1460-2075.1988.tb03306.x · DOI
- Kowal, 1989, Proc Natl Acad Sci USA, 86, 5810, 10.1073/pnas.86.15.5810 · DOI
- Misra, 1999, J Biol Chem, 274, 25785, 10.1074/jbc.274.36.25785 · DOI
- Curtin, 1996, Acta Diabetol, 33, 205, 10.1007/BF02048544 · DOI
- Karpe, 1999, Metabolism, 48, 301, 10.1016/S0026-0495(99)90076-8 · DOI
- Farese, 1996, Proc Natl Acad Sci USA, 93, 6393, 10.1073/pnas.93.13.6393 · DOI
- Véniant, 1998, J Clin Invest, 102, 1559, 10.1172/JCI4164 · DOI
- Kunjathoor, 1996, J Clin Invest, 97, 1767, 10.1172/JCI118604 · DOI
- Havel, 1955, J Clin Invest, 34, 1345, 10.1172/JCI103182 · DOI
- Shachter, 1996, J Clin Invest, 98, 846, 10.1172/JCI118857 · DOI
- de Silva, 1994, J Biol Chem, 269, 2324, 10.1016/S0021-9258(17)42171-5 · DOI
- McCormick, 1996, J Biol Chem, 271, 11963, 10.1074/jbc.271.20.11963 · DOI
- Smith, 1990, J Biol Chem, 265, 14709, 10.1016/S0021-9258(18)77166-4 · DOI
- Chen, 1994, J Lipid Res, 35, 1918, 10.1016/S0022-2275(20)39938-7 · DOI
- Aalto-Setälä, 1992, J Clin Invest, 90, 1889, 10.1172/JCI116066 · DOI
- Jong, 1996, Arterioscler Thromb Vasc Biol, 16, 934, 10.1161/01.ATV.16.8.934 · DOI
- Baginsky, 1977, J Lipid Res, 18, 423, 10.1016/S0022-2275(20)41659-1 · DOI
- Paigen, 1985, Atherosclerosis, 57, 65, 10.1016/0021-9150(85)90138-8 · DOI
- Bilheimer, 1972, Biochim Biophys Acta, 26, 212, 10.1016/0005-2760(72)90034-3 · DOI
- Ramakrishnan, 1990, J Lipid Res, 31, 1031, 10.1016/S0022-2275(20)42743-9 · DOI
- Wu, 1997, J Biol Chem, 272, 20627, 10.1074/jbc.272.33.20627 · DOI
- Paka, 1999, J Biol Chem, 274, 4816, 10.1074/jbc.274.8.4816 · DOI
- Pillarisetti, 1992, J Biol Chem, 267, 16517, 10.1016/S0021-9258(18)42033-9 · DOI
- Obunike, 1996, J Lipid Res, 37, 2439, 10.1016/S0022-2275(20)37492-7 · DOI
- Obunike, 2000, Arterioscler Thromb Vasc Biol, 20, 111, 10.1161/01.ATV.20.1.111 · DOI
- Wagner, 1981, Arteriosclerosis, 1, 192, 10.1161/01.ATV.1.3.192 · DOI
- Choi, 1993, J Biol Chem, 268, 15804, 10.1016/S0021-9258(18)82326-2 · DOI
- Roskams, 1995, Hepatology, 21, 950, 10.1002/hep.1840210410 · DOI
- Kako, 1999, J Lipid Res, 40, 2185, 10.1016/S0022-2275(20)32093-9 · DOI
- Bar-on, 1981, Diabetes, 30, 496, 10.2337/diab.30.6.496 · DOI
- Laakso, 1987, Diabetologia, 30, 703, 10.1007/BF00296992 · DOI
- Hansen, 1997, J Diabetes Complications, 11, 230, 10.1016/S1056-8727(96)00048-7 · DOI
- Donner, 1998, J Lipid Res, 39, 1805, 10.1016/S0022-2275(20)32168-4 · DOI
- Hegele, 1998, Arterioscler Thromb Vasc Biol, 18, 1212, 10.1161/01.ATV.18.8.1212 · DOI
- Boisfer, 1999, J Biol Chem, 274, 11564, 10.1074/jbc.274.17.11564 · DOI
- Weisgraber, 1990, J Biol Chem, 265, 22453, 10.1016/S0021-9258(18)45726-2 · DOI
- Jong, 1996, J Clin Invest, 98, 2259, 10.1172/JCI119036 · DOI
- Mahley, 1999, J Lipid Res, 40, 1, 10.1016/S0022-2275(20)33334-4 · DOI · Paper page
- Ji, 1995, J Lipid Res, 36, 583, 10.1016/S0022-2275(20)39892-8 · DOI
- Willnow, 1994, Science, 264, 1471, 10.1126/science.7515194 · DOI
- Ishibashi, 1994, Proc Natl Acad Sci USA, 91, 4431, 10.1073/pnas.91.10.4431 · DOI · Paper page
- Ji, 1993, J Biol Chem, 268, 10160, 10.1016/S0021-9258(18)82186-X · DOI · Paper page
- Al-Haideri, 1997, Biochemistry, 36, 12766, 10.1021/bi9631024 · DOI
- Kjellen, 1983, Diabetes, 32, 337, 10.2337/diab.32.4.337 · DOI · Paper page
- Spiro, 1987, Diabetologia, 30, 259, 10.1007/BF00270425 · DOI
- Unger, 1991, J Biol Chem, 266, 8671, 10.1016/S0021-9258(18)31496-0 · DOI · Paper page
- Kofoed-Enevoldsen, 1993, Diabetologia, 36, 310, 10.1007/BF00400233 · DOI
- Park, 1998, Nat Med, 4, 1025, 10.1038/2012 · DOI
- Rescan, 1993, Am J Pathol, 142, 199
- van der Woude, 1997, Exp Nephrol, 5, 180
- Bollineni, 1997, Curr Eye Res, 16, 127, 10.1076/ceyr.16.2.127.5089 · DOI
- Yokoyama, 1997, Diabetes, 46, 1875, 10.2337/diab.46.11.1875 · DOI
- Kanwar, 1996, J Clin Invest, 98, 2478, 10.1172/JCI119066 · DOI
- Templeton, 1996, Metabolism, 45, 1136, 10.1016/S0026-0495(96)90014-1 · DOI
- Jensen, 1997, Diabetes, 46(Suppl. 2), S98, 10.2337/diab.46.2.S98 · DOI
- Kjellen, 1983, Diabetes, 32, 337, 10.2337/diab.32.4.337 · DOI · Paper page
- Spiro, 1987, Diabetologia, 30, 259, 10.1007/BF00270425 · DOI
- Unger, 1991, J Biol Chem, 266, 8671, 10.1016/S0021-9258(18)31496-0 · DOI · Paper page
- Curtin, 1996, Acta Diabetol, 33, 205, 10.1007/BF02048544 · DOI
Cited by
Sorted by citations
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Kavey, R.-E. W., Allada, V., Daniels, S. R., Hayman, L. L., McCrindle, B. W., Newburger, J. W., Parekh, R. S., & Steinberger, J. (2006) · Circulation · doi:10.1161/circulationaha.106.179568 · Cited by 707
Chahil, T. J., & Ginsberg, H. N. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2006.06.002 · Cited by 233
Stanford, K. I., Bishop, J. R., Foley, E. M., Gonzales, J. C., Niesman, I. R., Witztum, J. L., & Esko, J. D. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38251 · Cited by 226
Metadata
- Authors
- Ebara, T., Conde, K., Kako, Y., Liu, Y., Xu, Y., Ramakrishnan, R., Goldberg, I. J., & Shachter, N. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2000-06-15
- Volume
- 105
- Issue
- 12
- Pages
- 1807-1818
- ISSN
- 0021-9738
- Cited by
- 86
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. https://app.cochat.ai/papers/10.1172/jci8283
- The paper
- Ebara, T., Conde, K., Kako, Y., Liu, Y., Xu, Y., Ramakrishnan, R., Goldberg, I. J., & Shachter, N. S. (2000). Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. Journal of Clinical Investigation. https://doi.org/10.1172/jci8283
